Reduce use of long-acting β2-agonists in asthma therapy, FDA says

Thompson, Cheryl A.
April 2010
American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p504
Academic Journal
The article reports on the risks of long-acting β2-adrenergic agonists (LABAs) for asthma therapy and on the recommendations of the U.S. Food and Drug Administration (FDA) related to LABAs. It states that FDA had concluded that asthmatic people who use LABA have risk for exacerbation of the symptoms of asthma. Pulmonologists John K. Jenkins urges health care personnels to stop using LABA. Janet Woodcock of FDA had declared that LABAs is not a medication that can control asthma.


Related Articles

  • Asthma market plagued by ingredient inquiries.  // Drug Store News;1/19/2009, Vol. 31 Issue 1, p32 

    The article reports that about 6 million people in the U.S. use asthma drugs known as long-acting beta-agonists (LABAs) to control their asthma symptoms, but they might soon have to start looking for alternatives. According to the officials of the Food and Drug Administration (FDA), early in...

  • FDA curbs LABA use for asthma.  // Drug Topics;Mar2010, Vol. 154 Issue 3, p12 

    The article reports on the limitations recommended by the U.S. Food and Drug Administration (FDA) in using long-acting beta2-adrenergic agonists (LABAs) in the treatment of asthma. It mentions that the decision was made due to the increasing death rates connected with LABA use. It adds that the...

  • FDA imposes new safety requirements to curb use of LABAs in asthma patients.  // Formulary;Mar2010, Vol. 45 Issue 3, p104 

    The article focuses on U.S. Food and Drug Administration (FDA) recommendations to limit the use of long-acting beta2-adrenergic agonists (LABAs) for the treatment of asthma. Results of a surveillance study indicated that LABAs increased the risk of severe exacerbation of asthma symptoms,...

  • COMMITTEE WEIGHS IN ON ASTHMA MEDS.  // RN;Feb2009, Vol. 72 Issue 2, p17 

    The article discusses the potential for the U.S. Food and Drug Administration to ban the use of long-acting beta agonists (LABAs) almeterol and formoterol monotherapy for the treatment of asthma in adults and children. Executive vice president of the American Academy of Allergy, Asthma, and...

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Feb2009 Pharmacology Watch, p2 

    The article presents updates on the U.S. Food and Drug Administration (FDA). The agency has decided to require a boxed warning on sodium phosphate bowel-cleansing products due to the risk of acute phosphate nephropathy linked to the use of these products. The agency is planning to impose a ban...

  • FDA actions. Elliott, William T. // Clinical Cardiology Alert;Apr2010 Pharmacology Watch, p2 

    The article offers updates on the actions of the U.S. Food and Drug Administration (FDA) in 2010. The agency has released a warning claiming that long-acting beta agonists (LABAs) should not be taken alone in asthma therapy in children and adults. The agency has decided to approve the monoclonal...

  • The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility? Sears, Malcolm R. // Thorax;Feb2013, Vol. 68 Issue 2, p195 

    The author presents his views on the guidelines issued by the U.S. Food and Drugs Administration (FDA) that made trials compulsory to examine the safety of long-acting beta-agonists (LABAs) in asthma. He refers to controversies regarding the use of salmeterol, developed by the pharmaceutical...


    The article reports that a U.S. Federal Drug Administration committee has recommended that the beta-2 agonists formoterol fumarate (Foradil) and salmeterol xinafoate no longer be used to treat asthma. The combination products fluticasone propionate and salmeterol (Advair) and...

  • FDA Panel: Ban 2 Popular Asthma Drugs. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;1/28/2009, Vol. 301 Issue 4, p365 

    The article reports that a panel of advisors to the U.S. Food and Drug Administration has recommended that the agency ban long-acting β-agonist (LABA) drugs formoterol and salmeterol. Products which contain a combination of LABA and inhaled corticosteroid were also evaluated and found to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics